Enanta Pharmaceuticals (ENTA) Non-Current Assets (2012 - 2026)

Enanta Pharmaceuticals has reported Non-Current Assets for 15 years, with the latest figure at $136.3 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 70.08% year-over-year to $136.3 million; the trailing twelve-month figure through Mar 2026 stood at $421.8 million (up 20.64% YoY), and the FY2025 full-year result was $76.4 million, down 0.53% from the prior year.
• Non-Current Assets for Q1 2026 stood at $136.3 million, up from $130.8 million in the prior quarter.
• The five-year high for Non-Current Assets was $136.3 million in Q1 2026, with the low at $38.2 million in Q4 2023.
• Historically, Non-Current Assets has averaged $75.2 million across 5 years, with a median of $72.2 million in 2022.
• Annual changes were most pronounced in 2022 — Non-Current Assets sank 46.82% — and 2024, when it surged 140.32%.
• Enanta Pharmaceuticals' Non-Current Assets stood at $63.8 million in 2022, then sank by 40.16% to $38.2 million in 2023, then soared by 110.75% to $80.5 million in 2024, then surged by 62.51% to $130.8 million in 2025, then grew by 4.18% to $136.3 million in 2026.
• The last three Non-Current Assets figures came in at $136.3 million (Q1 2026), $130.8 million (Q4 2025), and $76.4 million (Q3 2025), per Business Quant data.